Lek Obtains Another Approval to Market Co-Amoxiclav in the US Market
Ljubljana, 29 November 2002 – The Slovenian pharmaceutical company Lek d.d. received another final approval from the US regulatory authorities (Food and Drug Administration) to immediately start the distribution and sales of the 625-milligram tablets of co-amoxiclav (combination of amoxicilline antibiotic and clavulanic acid, beta-lactamase inhibitor), an antibiotic for treatment of broad-spectrum bacterial infections.
The Slovenian pharmaceutical company Lek has recently received final approval to immediately start the distribution and sales of the 1-gram tablets of co-amoxiclav. On 27 November Lek d.d. received one more approval, this time for 625-milligram tablets of co-amoxiclav. Lek will market the product through its US subsidiary Lek Pharmaceuticals Inc.
The US market is the world’s largest pharmaceutical market and one of Lek’s strategic markets. The pharmaceutical company Lek will start marketing 625-milligram and 1-gram co-amoxiclav tablets in the US market in the beginning of 2003.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information, please contact: +386 1 580 22 43 Miša Komar iberna, Lek’s Corporate Communications